Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals

Sundial Growers Inc. (Sundial), a Canadian licensed producer of cannabis and Crescita Therapeutics Inc. (Crescita), a Canadian commercial dermatology company, recently announced a development and licensing agreement granting Sundial the worldwide rights to Crescita's proprietary transdermal delivery technologies for the development of topicals containing cannabis and hemp.

The partnership combines Crescita's leading expertise in dermal sciences and in the development of patented topical formulations with Sundial's cannabis production, extraction and commercialization expertise. The agreement will enable the development of unique, high-quality cannabis and hemp topicals for the Canadian and international non-prescription markets.

"We are thrilled to establish this important partnership with Sundial, a visionary in crafting premium cannabis brands and a company that shares our passion for innovation," said Serge Verreault, President and CEO of Crescita. "This milestone underscores the strength of our IP and technologies in providing a differentiating factor in the cannabis market and is a step forward in making Crescita a leading dermatology company."

Annie Gauthier and Gino Martel, partners of BCF, acted for Crescita in this operation. BCF provides smart and creative solutions based on industry insight to innovators and investors leading the way in the life sciences and cannabis sectors.

To read  the official press release issued on October 28, 2019,  click here.